{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:04:46Z","timestamp":1761491086041},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>We previously described an increased immune response 28 days after a booster dose of the live, attenuated, tetravalent dengue vaccine (CYD-TDV) in healthy adolescents and adults in Latin America (CYD64, NCT02623725). This follow-up study evaluated immune response persistence and safety of a CYD-TDV booster dose up to Month (M) 24 post-booster.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This study included 250 participants who previously received 3 primary doses of CYD-TDV in the CYD13 (NCT00993447) and CYD30 (NCT01187433) studies, and who were randomized 4\u20135 years later to receive a CYD-TDV booster or placebo (3:1). Dengue neutralizing antibodies against the parental dengue virus strains were assessed using the plaque reduction neutralization test (PRNT<jats:sub>50<\/jats:sub>) at M6, M12, and M24 post-booster. Post-booster memory B-cell responses were assessed in a subset of participants using the FluoroSpot assay up to M12 post-booster.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In the CYD-TDV group (n = 187), dengue neutralizing antibody geometric mean titers (GMTs) declined from the peak at day 28 through to M24 for all serotypes. GMTs at M24 were similar to those at pre-booster among baseline dengue seropositives. A similar trend was observed for baseline dengue seronegatives, albeit at a lower magnitude. Previous vaccination-induced detectable B-cell memory responses in seropositives and seronegatives that decreased to pre-booster levels at M12 post-booster. The CYD-TDV booster dose was well-tolerated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>In baseline dengue seropositives, following a CYD-TDV booster dose administered 4\u20135 years after primary immunization, dengue neutralizing antibody GMTs and B-cell memory responses peaked in the short-term before gradually decreasing over time. A CYD-TDV booster dose could improve protection against dengue during outbreak periods.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000002830","type":"journal-article","created":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T01:01:07Z","timestamp":1599872467000},"page":"961-968","source":"Crossref","is-referenced-by-count":6,"title":["Immune Response Persistence and Safety of a Booster Dose of the Tetravalent Dengue Vaccine in Adolescents and Adults Who Previously Completed the 3-dose Schedule 4\u20135 Years Earlier in Latin America"],"prefix":"10.1097","volume":"39","author":[{"given":"Diana","family":"Coronel","sequence":"first","affiliation":[{"name":"Clinical Sciences, Sanofi Pasteur, Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enid J.","family":"Garc\u00eda-Rivera","sequence":"additional","affiliation":[{"name":"Endowed Health Services Research Center, University of Puerto Rico School of Medicine, Medical Sciences Campus, San Juan, Puerto Rico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doris Maribel","family":"Rivera","sequence":"additional","affiliation":[{"name":"Inversiones en Investigaci\u00f3n M\u00e9dica S.A. INVERIME S.A, Tegucigalpa, Honduras"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"Arredondo-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Pediatr\u00eda Clinical Research Unit, Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reynaldo","family":"Dietze","sequence":"additional","affiliation":[{"name":"Universidade Federal do Espirito Santo, N\u00facleo de Doen\u00e7as Infecciosas\/CBM\/UFES, Vitoria, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Paula","family":"Perroud","sequence":"additional","affiliation":[{"name":"Clinical Sciences, Sanofi Pasteur, Sao Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Cort\u00e9s","sequence":"additional","affiliation":[{"name":"Global Health, Sanofi Pasteur, Bogot\u00e1, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Bonaparte","sequence":"additional","affiliation":[{"name":"Global Clinical Immunology, Sanofi Pasteur, Swiftwater, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Sciences and Operations, Sanofi, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anke","family":"Pagnon","sequence":"additional","affiliation":[{"name":"Research and External Innovation Department, Sanofi Pasteur, Marcy l\u2019Etoile, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Jantet-Blaudez","sequence":"additional","affiliation":[{"name":"Research and External Innovation Department, Sanofi Pasteur, Marcy l\u2019Etoile, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Andrey Rojas","family":"Pe\u00f1alosa","sequence":"additional","affiliation":[{"name":"Departamento de Producci\u00f3n, Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Asunci\u00f3n, Asunci\u00f3n, Paraguay"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo","family":"Dayan","sequence":"additional","affiliation":[{"name":"Clinical Sciences, Sanofi Pasteur, Swiftwater, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betzana","family":"Zambrano","sequence":"additional","affiliation":[{"name":"Clinical Sciences, Sanofi Pasteur, Montevideo, Uruguay"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos A.","family":"DiazGranados","sequence":"additional","affiliation":[{"name":"Global Clinical Science, Sanofi Pasteur, Marcy l\u2019Etoile, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Noriega","sequence":"additional","affiliation":[{"name":"Global Clinical Sciences, Sanofi Pasteur, Swiftwater, Pennsylvania."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"taz062","DOI":"10.1093\/jtm\/taz062","article-title":"Severe dengue in travellers: pathogenesis, risk and clinical management.","volume":"26","author":"Halstead","year":"2019","journal-title":"J Travel Med"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy.","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/S1473-3099(18)30494-8","article-title":"Deliberations of the strategic advisory group of experts on immunization on the use of CYD-TDV dengue vaccine.","volume":"19","author":"Wilder-Smith","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"taz092","DOI":"10.1093\/jtm\/taz092","article-title":"Dengue pre-vaccination serology screening for the use of Dengvaxia\u00ae.","volume":"26","author":"Hunsperger","year":"2019","journal-title":"J Travel Med"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"taz078","DOI":"10.1093\/jtm\/taz078","article-title":"Evaluation of rapid diagnostic tests and conventional enzyme-linked immunosorbent assays to determine prior dengue infection.","volume":"26","author":"Bonaparte","year":"2019","journal-title":"J Travel Med"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"114918","DOI":"10.1016\/j.diagmicrobio.2019.114918","article-title":"Evaluation of dengue serological tests available in Puerto Rico for identification of prior dengue infection for prevaccination screening.","volume":"96","author":"Bonaparte","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1080\/21645515.2017.1333211","article-title":"Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination.","volume":"13","author":"Vigne","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America.","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/infdis\/jix609","article-title":"Neutralizing antibody correlates analysis of tetravalent dengue vaccine efficacy trials in Asia and Latin America.","volume":"217","author":"Moodie","year":"2018","journal-title":"J Infect Dis"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1097\/INF.0000000000002286","article-title":"Dengue vaccine booster in healthy adolescents and adults in Latin America: evaluation 4-5 years after a primary 3-dose schedule.","volume":"38","author":"Coronel","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"R17-20230912","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/INF.0b013e31829b8022","article-title":"Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America.","volume":"32","author":"Villar","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.4269\/ajtmh.13-0304","article-title":"Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil.","volume":"89","author":"Dayan","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"962","DOI":"10.4269\/ajtmh.12-0461","article-title":"Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development.","volume":"88","author":"Timiryasova","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"825","DOI":"10.4269\/ajtmh.2009.08-0625","article-title":"Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance.","volume":"81","author":"Thomas","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial.","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"R22-20230912","doi-asserted-by":"crossref","first-page":"74","DOI":"10.5709\/acp-0133-x","article-title":"Confidence intervals for two sample means: calculation, interpretation, and a few simple rules.","volume":"9","author":"Pfister","year":"2013","journal-title":"Adv Cogn Psychol"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"e0006538","DOI":"10.1371\/journal.pntd.0006538","article-title":"Persistence of yellow fever virus outside the Amazon Basin, causing epidemics in Southeast Brazil, from 2016 to 2018.","volume":"12","author":"Rezende","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"issue":"suppl_10","key":"R24-20230912","doi-asserted-by":"crossref","first-page":"S906","DOI":"10.1093\/infdis\/jix513","article-title":"Humoral immune responses against Zika virus infection and the importance of preexisting flavivirus immunity.","volume":"216","author":"Priyamvada","year":"2017","journal-title":"J Infect Dis"},{"key":"R26-20230912","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.aag0219","article-title":"EPIDEMIOLOGY. Countering the Zika epidemic in Latin America.","volume":"353","author":"Ferguson","year":"2016","journal-title":"Science"},{"key":"R27-20230912","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3855\/jidc.8217","article-title":"Zika virus outbreak in Brazil.","volume":"10","author":"Heukelbach","year":"2016","journal-title":"J Infect Dev Ctries"},{"key":"R28-20230912","article-title":"Zika virus disease in Colombia \u2014 preliminary report.","author":"Pacheco","year":"2016","journal-title":"New Engl J Med"},{"key":"R29-20230912","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.3201\/eid2308.161944","article-title":"Real-time evolution of Zika virus disease outbreak, Roat\u00e1n, Honduras.","volume":"23","author":"Brooks","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"R30-20230912","doi-asserted-by":"crossref","first-page":"e0212114","DOI":"10.1371\/journal.pone.0212114","article-title":"Zika virus: Epidemiological surveillance of the Mexican Institute of Social Security.","volume":"14","author":"Grajales-Mu\u00f1iz","year":"2019","journal-title":"PLoS One"},{"key":"R31-20230912","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ijid.2017.07.017","article-title":"Zika virus epidemic in Puerto Rico: health justice too long delayed.","volume":"65","author":"Rodr\u00edguez-D\u00edaz","year":"2017","journal-title":"Int J Infect Dis"},{"key":"R32-20230912","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/ni.3515","article-title":"Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with Zika virus.","volume":"17","author":"Dejnirattisai","year":"2016","journal-title":"Nat Immunol"},{"key":"R33-20230912","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/21645515.2019.1661204","article-title":"Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5-6 years after completion of the primary series.","volume":"16","author":"Park","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"R34-20230912","doi-asserted-by":"crossref","first-page":"e0005224","DOI":"10.1371\/journal.pntd.0005224","article-title":"Dengue in Latin America: systematic review of molecular epidemiological trends.","volume":"11","author":"Ramos-Casta\u00f1eda","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"R35-20230912","doi-asserted-by":"crossref","first-page":"e0007389","DOI":"10.1371\/journal.pntd.0007389","article-title":"A 15-year review of dengue hospitalizations in Singapore: reducing admissions without adverse consequences, 2003 to 2017.","volume":"13","author":"Ang","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"R36-20230912","doi-asserted-by":"crossref","first-page":"e3230","DOI":"10.1371\/journal.pntd.0003230","article-title":"Dengue virus neutralizing antibody levels associated with protection from infection in Thai cluster studies.","volume":"8","author":"Buddhari","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"R37-20230912","first-page":"351","article-title":"Dissecting antibodies induced by a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in Naive and dengue-exposed individuals.","volume":"215","author":"Henein","year":"2017","journal-title":"J Infect Dis"},{"key":"R38-20230912","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1056\/NEJMoa066092","article-title":"Duration of humoral immunity to common viral and vaccine antigens.","volume":"357","author":"Amanna","year":"2007","journal-title":"N Engl J Med"},{"key":"R39-20230912","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-1-4939-8567-8_6","article-title":"Detection of cross-reactive B cells using the FluoroSpot assay.","volume":"1808","author":"Jahnmatz","year":"2018","journal-title":"Methods Mol Biol"},{"key":"R40-20230912","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1080\/21645515.2019.1578595","article-title":"Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials.","volume":"15","author":"Tran","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"R41-20230912","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.trivac.2015.03.002","article-title":"Immunogenicity and safety of a tetravalent dengue vaccine during a five-year follow-up period.","volume":"4","author":"Capeding","year":"2015","journal-title":"Trials Vaccinol"},{"key":"R42-20230912","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3389\/fimmu.2019.01956","article-title":"Can complementary prime-boost immunization strategies be an alternative and promising vaccine approach against dengue virus?","volume":"10","author":"Vald\u00e9s","year":"2019","journal-title":"Front Immunol"},{"key":"R43-20230912","doi-asserted-by":"crossref","first-page":"e0005554","DOI":"10.1371\/journal.pntd.0005554","article-title":"Dissecting the human serum antibody response to secondary dengue virus infections.","volume":"11","author":"Patel","year":"2017","journal-title":"PLoS Negl Trop Dis"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002830","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:46:11Z","timestamp":1694558771000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002830"}},"subtitle":["A Randomized Placebo-controlled Trial"],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002830","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}